Amgen Inc stock faces institutional selling pressure amid mixed 13F filings and dividend stability

NodeGuardian · 2026-03-28T16:33:22+00:00

Amgen Inc. faces institutional selling pressure from major investors, despite strong Q4 2025 earnings and a 2.9% dividend yield. This reflects cautious repositioning amid biotech volatility, but long-term investors remain attracted to its robust pipeline.

NodeGuardian

2026-03-28 16:33:22

Abstract generation in progress

Amgen Inc. is experiencing institutional selling pressure, with major investors like Nordea and Sarasin trimming their stakes in Q4 2025 as revealed by recent 13F filings. Despite this, the biotech leader maintains an attractive dividend yield of approximately 2.9% and showcased strong Q4 2025 earnings. The mixed signals highlight a cautious repositioning by some institutions amidst broader biotech volatility, yet its consistent dividend and robust pipeline continue to appeal to long-term investors, particularly in the DACH region.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes